50488-44-3

Basic information

• Product Name: 4-BROMO-2-METHYLQUINOLINE
• Synonyms: 4-BROMO-2-METHYLQUINOLINE;2-Methyl-4-broMoquinoline;4-Bromoquinaldine
• CAS NO: 50488-44-3
• Molecular Formula: C₁₀H₈BrN
• Molecular Weight: 222.08122
• EINECS: -0
• Mol File: 50488-44-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 88-90℃ (1 Torr)
• Flash Point: 135.635 °C
• Appearance: /
• Density: 1.488 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.21±0.50(Predicted)
• CAS DataBase Reference: 4-BROMO-2-METHYLQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-METHYLQUINOLINE(50488-44-3)
• EPA Substance Registry System: 4-BROMO-2-METHYLQUINOLINE(50488-44-3)

Safety Data

• Hazardous Substances Data: 50488-44-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-methylquinoline is a chemical compound with the molecular formula C10H8BrN. It is a member of the quinoline family and contains a bromine atom and a methyl group attached to the quinoline ring. 4-Bromo-2-methylquinoline is commonly used as a building block in organic synthesis and pharmaceutical research. It is known for its potential biological activities and has been studied for its antimicrobial, antifungal, and anticancer properties. 4-Bromo-2-methylquinoline may also be used as a reagent in various chemical reactions due to its unique structural features. Overall, this compound has diverse applications in both scientific research and industrial processes.

InChI:InChI=1/C10H8BrN/c1-7-6-9(11)8-4-2-3-5-10(8)12-7/h2-6H,1H3

Upstream product

• 1076-28-4 2-methylquinoline N-oxide 
• 62-53-3 aniline 
• 607-67-0 4-hydroxy-2-methylquinoline 
• 7789-59-5 phosphorus(V) oxybromide 
• 607-66-9 4-methylquinolin-2-ol 

Downstream Products

• 461665-75-8 methyl 4-[hydroxy(2-methyl-4-quinolinyl)methyl]benzoate 
• 461665-77-0 methyl 4-[(2-methyl-4-quinolinyl)methyl]benzoate 
• 461665-78-1 4-[(2-methyl-4-quinolinyl)methyl]benzoic acid 
• 461665-76-9 methyl 4-{(2-methyl-4-quinolinyl)[(methylsulfonyl)oxy]methyl}benzoate 
• 936491-30-4 4-[4-(2-methyl-quinolin-4-ylmethyl)-benzoylamino]-tetrahydro-pyran-3-carboxylic acid methyl ester 
• 477585-40-3 4-(2-methyl-4-quinolinyl)benzoic acid 
• 6760-22-1 2-methylquinoline-4-carboxaldehyde 
• 6628-04-2 4-amino-2-methylquinoline 
• 91-63-4 2-methylquinoline 
• 5470-96-2 quinoline 2-carbaldehyde 
• 6287-63-4 3-(quinolin-2-yl)prop-2-enoic acid 
• 13235-12-6 4-bromo-2-methylquinolin-3-ol 
• 1345515-22-1 2-methyl-3-hydroxy-4-acetylquinoline 
• 28615-70-5 4-bromoquinoline-2-carbaldehyde 

Relevant articles and documents

CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF

Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents

An analogous library of 2-substituted quinoline compounds was synthesized with the aim to identify a potential drug candidate to treat visceral leishmaniasis. These molecules were tested for their in vitro and in vivo biological activity against Leishmania donovani. Metabolic stability of these compounds was also improved through the introduction of halogen substituents. Compound (26g), found to be the most active; exhibited an IC50 value of 0.2 μM and >180 fold selectivity. The hydrochloride salt of (26g) showed 84.26 ± 4.44 percent inhibition at 50 mg/kg × 5 days (twice daily, oral route) dose in L. donovani/hamster model. The efficacy was well correlated with the PK data observed which indicating that the compound is well distributed.

Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.